JAK2 and COVID-19: Restrictions for costly therapies, such as IL-6 inhibitors and JAK-2 inhibitors, were also common during the pandemic.10 Our experience mirrors these findings, underscoring the importance of formulary restrictions in guiding COVID-19 treatment strategies and its ability to adapt to evolving data.